Clinical Trial: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
In: US Fed News (USA), 2022-12-13, S. 1
Zeitungsartikel
Zugriff:
U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT05646381) titled 'A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis' on Dec. 2. Brief Summary: The purpose of this study is to evaluate the efficacy and safety of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis...
Titel: |
Clinical Trial: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
|
---|---|
Zeitschrift: | US Fed News (USA), 2022-12-13, S. 1 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|